Recombinant Antigen Based Sero-Diagnosis of Infectious Bursal Disease (IBD) By Indirect ELISA
Background:
Infectious bursal disease is an economically important disease of poultry causing immunosuppression and predisposing them to other infections. Serological diagnosis is commonly performed with agar gel immuno diffusion (AGID) test, virus neutralization (VN) test or enzyme linked immunosorbent assay (ELISA). AGID test is the simplest assay, but its sensitivity and specificity may vary from laboratory to laboratory and moreover it is time consuming. VN has the highest specificity and VN antibody test correlates with protection. But as VN is labour intensive, and requires the facilities of virology laboratory and as it provides delayed results, it is unpractical for routine use.
Technology Details
Recombinant antigen-based diagnostics are a new class of diagnostic tools which could replace the conventional methods based on whole cell antigens. This ensures that there is no risk involved for both the producer and the user in handling of live organisms. The recombinant antigen developed in this technology is specific for all the strains of infectious bursal disease virus. Moreover, it is useful to assess the immune status of vaccinated birds and management of large flocks. The assay can monitor the efficacy of live and killed IBD vaccines. The kit is available in the form of recombinant antigen coated ELISA plates with a shelf life of 6 months under refrigerated condition. Patent Number 277404 for the recombinant antigen that was used to develop a single serum dilution ELISA for the serodiagnosis of IBD